Acuitive Technologies Launches Citregraft Bone Graft Substitute

Acuitive Technologies commenced commercialization of Citregraft with its first use in a surgical case.

Leveraging the benefits of citrate in bone anatomy and physiology, Acuitive Technologies developed Citregen, a citrate-based polymer technology that mimics natural bone chemistry and supplies the energy needed for regeneration. Exclusively made with Citregen and bioactive glass, Citregraft is a highly porous and bioactive synthetic bone graft substitute designed to interact with proteins to regenerate bony voids within the skeletal system.

Citregraft benefits include:

• Bioactive formulation to improve graft integration
• Easily morselized to fill and hold its position within irregular defects
• Absorbs five times its weight in fluids
• Synergizes with bone marrow aspirate to bind proteins
• Citrate increases cell energy for tissue regeneration

Citregraft offers an alternative to conventional bone graft substitutes by improving handling, liquid uptake, and protein binding.

Source: Acuitive Technologies, Inc.